The aggregate of these observations establishes a robust evidentiary foundation for the legitimate extrapolation of in vitro findings to in vivo and clinical paradigms, thereby markedly enhancing the prospective utility of PI3K/AKT/mTOR-oriented strategies in the personalized treatment of arthritis. The gene discussed is MTOR; the disease is arthritic joint disease.